[2]
Nawaz A, Zaib S, Khan I, Ahmed A, Shahzadi K, Riaz H. Silybum marianum: An Overview of its Phytochemistry and Pharmacological Activities with Emphasis on Potential Anticancer Properties. Anti-cancer agents in medicinal chemistry. 2023:23(13):1519-1534. doi: 10.2174/1871520623666230412111152. Epub
[PubMed PMID: 37055902]
Level 3 (low-level) evidence
[3]
Bijak M. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism. Molecules (Basel, Switzerland). 2017 Nov 10:22(11):. doi: 10.3390/molecules22111942. Epub 2017 Nov 10
[PubMed PMID: 29125572]
[4]
Dwyer JT, Coates PM, Smith MJ. Dietary Supplements: Regulatory Challenges and Research Resources. Nutrients. 2018 Jan 4:10(1):. doi: 10.3390/nu10010041. Epub 2018 Jan 4
[PubMed PMID: 29300341]
[6]
Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (Baltimore, Md.). 2005 Jul:42(1):44-52
[PubMed PMID: 15895401]
[7]
Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Journal of hepatology. 1997 Apr:26(4):871-9
[PubMed PMID: 9126802]
[8]
Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepatitis monthly. 2012 Aug:12(8):e6099. doi: 10.5812/hepatmon.6099. Epub 2012 Aug 3
[PubMed PMID: 23087748]
Level 3 (low-level) evidence
[9]
Kazazis CE, Evangelopoulos AA, Kollas A, Vallianou NG. The therapeutic potential of milk thistle in diabetes. The review of diabetic studies : RDS. 2014 Summer:11(2):167-74. doi: 10.1900/RDS.2014.11.167. Epub 2014 Aug 10
[PubMed PMID: 25396404]
[10]
Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytotherapy research : PTR. 2006 Dec:20(12):1036-9
[PubMed PMID: 17072885]
Level 1 (high-level) evidence
[11]
Loguercio C, Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Niosi M, D'Auria MV, Capasso R, Del Vecchio Blanco C, Real Sud Group. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Digestive diseases and sciences. 2007 Sep:52(9):2387-95
[PubMed PMID: 17410454]
Level 3 (low-level) evidence
[12]
Hruby K, Csomos G, Fuhrmann M, Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Human toxicology. 1983 Apr:2(2):183-95
[PubMed PMID: 6862461]
[13]
Rahnama S, Tehrankhah ZM, Mohajerani F, Mohammadi FS, Yeganeh ZY, Najafi F, Babashah S, Sadeghizadeh M. Milk thistle nano-micelle formulation promotes cell cycle arrest and apoptosis in hepatocellular carcinoma cells through modulating miR-155-3p /SOCS2 /PHLDA1 signaling axis. BMC complementary medicine and therapies. 2023 Sep 26:23(1):337. doi: 10.1186/s12906-023-04168-5. Epub 2023 Sep 26
[PubMed PMID: 37749575]
[14]
Jo AI, Kim MM. Silibinin Inhibits Cell Invasion through the Inhibition of MMPs, p-p38, and IL-1β in Human Fibrosarcoma Cells. Frontiers in bioscience (Landmark edition). 2023 Apr 6:28(4):64. doi: 10.31083/j.fbl2804064. Epub
[PubMed PMID: 37114542]
[15]
Iqbal MA, Chattopadhyay S, Siddiqui FA, Ur Rehman A, Siddiqui S, Prakasam G, Khan A, Sultana S, Bamezai RN. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications. The FEBS journal. 2021 Jan:288(2):471-485. doi: 10.1111/febs.15353. Epub 2020 May 28
[PubMed PMID: 32356386]
[16]
Kawaguchi-Suzuki M, Frye RF, Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Markowitz JS. The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. Drug metabolism and disposition: the biological fate of chemicals. 2014 Oct:42(10):1611-6. doi: 10.1124/dmd.114.057232. Epub 2014 Jul 15
[PubMed PMID: 25028567]
[17]
Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World journal of gastroenterology. 2011 May 14:17(18):2288-301. doi: 10.3748/wjg.v17.i18.2288. Epub
[PubMed PMID: 21633595]
[18]
Abenavoli L, Bellentani S. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? Expert review of gastroenterology & hepatology. 2013 Nov:7(8):677-9. doi: 10.1586/17474124.2013.842893. Epub 2013 Oct 17
[PubMed PMID: 24134155]
[19]
Schümann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Silibinin protects mice from T cell-dependent liver injury. Journal of hepatology. 2003 Sep:39(3):333-40
[PubMed PMID: 12927918]
[20]
Beyoğlu D, Idle JR. Metabolomic insights into the mode of action of natural products in the treatment of liver disease. Biochemical pharmacology. 2020 Oct:180():114171. doi: 10.1016/j.bcp.2020.114171. Epub 2020 Jul 22
[PubMed PMID: 32710968]
[21]
Trouillas P, Marsal P, Svobodová A, Vostálová J, Gazák R, Hrbác J, Sedmera P, Kren V, Lazzaroni R, Duroux JL, Walterová D. Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study. The journal of physical chemistry. A. 2008 Feb 7:112(5):1054-63. doi: 10.1021/jp075814h. Epub 2008 Jan 15
[PubMed PMID: 18193843]
[22]
Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2001:15(7):465-89
[PubMed PMID: 11520257]
[23]
Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World journal of hepatology. 2013 Mar 27:5(3):109-13. doi: 10.4254/wjh.v5.i3.109. Epub
[PubMed PMID: 23556042]
[24]
Borsari M, Gabbi C, Ghelfi F, Grandi R, Saladini M, Severi S, Borella F. Silybin, a new iron-chelating agent. Journal of inorganic biochemistry. 2001 Jun:85(2-3):123-9
[PubMed PMID: 11410232]
[25]
Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, Ten Dijke P, IT-LIVER Consortium. TGF-β signalling and liver disease. The FEBS journal. 2016 Jun:283(12):2219-32. doi: 10.1111/febs.13665. Epub 2016 Feb 22
[PubMed PMID: 26807763]
[26]
Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Patrick KS, Markowitz JS. An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study. Drug metabolism and disposition: the biological fate of chemicals. 2013 Sep:41(9):1679-85. doi: 10.1124/dmd.113.052423. Epub 2013 Jul 8
[PubMed PMID: 23835761]
[27]
Calani L, Brighenti F, Bruni R, Del Rio D. Absorption and metabolism of milk thistle flavanolignans in humans. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2012 Dec 15:20(1):40-6. doi: 10.1016/j.phymed.2012.09.004. Epub 2012 Oct 13
[PubMed PMID: 23072776]
[28]
Raclariu-Manolică AC, Socaciu C. Detecting and Profiling of Milk Thistle Metabolites in Food Supplements: A Safety-Oriented Approach by Advanced Analytics. Metabolites. 2023 Mar 17:13(3):. doi: 10.3390/metabo13030440. Epub 2023 Mar 17
[PubMed PMID: 36984880]
[29]
Rafieian-Kopaie M, Nasri H. Silymarin and diabetic nephropathy. Journal of renal injury prevention. 2012:1(1):3-5. doi: 10.12861/jrip.2012.02. Epub 2012 Jan 1
[PubMed PMID: 25340091]
[30]
Soleimani V, Delghandi PS, Moallem SA, Karimi G. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phytotherapy research : PTR. 2019 Jun:33(6):1627-1638. doi: 10.1002/ptr.6361. Epub 2019 May 8
[PubMed PMID: 31069872]
[32]
Wanwimolruk S, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). EXCLI journal. 2014:13():347-91
[PubMed PMID: 26417265]
[33]
Hatfield J, Saad S, Housewright C. Dietary supplements and bleeding. Proceedings (Baylor University. Medical Center). 2022:35(6):802-807. doi: 10.1080/08998280.2022.2121575. Epub 2022 Sep 15
[PubMed PMID: 36304597]
[34]
Necyk C, Zubach-Cassano L. Natural Health Products and Diabetes: A Practical Review. Canadian journal of diabetes. 2017 Dec:41(6):642-647. doi: 10.1016/j.jcjd.2017.06.014. Epub 2017 Aug 18
[PubMed PMID: 28826695]
[35]
Gufford BT, Chen G, Vergara AG, Lazarus P, Oberlies NH, Paine MF. Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction. Drug metabolism and disposition: the biological fate of chemicals. 2015 Sep:43(9):1353-9. doi: 10.1124/dmd.115.065086. Epub 2015 Jun 12
[PubMed PMID: 26070840]
[36]
Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integrative cancer therapies. 2007 Jun:6(2):146-57
[PubMed PMID: 17548793]